For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Heron Therapeutics Inc (NASDAQ: HRTX) closed at $1.3 in the last session, up 5.69% from day before closing price of $1.23. In other words, the price has increased by $5.69 from its previous closing price. On the day, 1.5 million shares were traded. HRTX stock price reached its highest trading level at $1.3 during the session, while it also had its lowest trading level at $1.21.
Ratios:
We take a closer look at HRTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.53 and its Current Ratio is at 0.82.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 09, 2025, initiated with a Buy rating and assigned the stock a target price of $6.
On June 13, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $7. On April 23, 2024, CapitalOne started tracking the stock assigning a Overweight rating and target price of $6.CapitalOne initiated its Overweight rating on April 23, 2024, with a $6 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 08 ’25 when Rubric Capital Management LP bought 2,387,225 shares for $1.50 per share. The transaction valued at 3,580,838 led to the insider holds 29,100,728 shares of the business. Morgan Adam bought 1,766,546 shares of HRTX for $2,649,819 on Aug 08 ’25. The Director now owns 8,753,290 shares after completing the transaction at $1.50 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRTX now has a Market Capitalization of 238309072 and an Enterprise Value of 335389344. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.59. Its current Enterprise Value per Revenue stands at 2.24 whereas that against EBITDA is 94.316.
Stock Price History:
The Beta on a monthly basis for HRTX is 1.26, which has changed by -0.3367347 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, HRTX has reached a high of $2.68, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -15.05%, while the 200-Day Moving Average is calculated to be -29.54%.
Shares Statistics:
According to the various share statistics, HRTX traded on average about 1.72M shares per day over the past 3-months and 1586830 shares per day over the past 10 days. A total of 183.31M shares are outstanding, with a floating share count of 181.54M. Insiders hold about 0.97% of the company’s shares, while institutions hold 74.20% stake in the company. Shares short for HRTX as of 1756425600 were 32387957 with a Short Ratio of 18.85, compared to 1753920000 on 35256448. Therefore, it implies a Short% of Shares Outstanding of 32387957 and a Short% of Float of 27.43.
Earnings Estimates
Heron Therapeutics Inc (HRTX) is currently under the scrutiny of 3.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.01, with high estimates of $0.0 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.0 and -$0.05 for the fiscal current year, implying an average EPS of -$0.03. EPS for the following year is $0.03, with 2.0 analysts recommending between $0.07 and -$0.02.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $39.03M. It ranges from a high estimate of $39.6M to a low estimate of $38.02M. As of the current estimate, Heron Therapeutics Inc’s year-ago sales were $32.81MFor the next quarter, 4 analysts are estimating revenue of $41.35M. There is a high estimate of $44.4M for the next quarter, whereas the lowest estimate is $38.9M.
A total of 4 analysts have provided revenue estimates for HRTX’s current fiscal year. The highest revenue estimate was $159.9M, while the lowest revenue estimate was $153.03M, resulting in an average revenue estimate of $156.48M. In the same quarter a year ago, actual revenue was $144.28MBased on 3 analysts’ estimates, the company’s revenue will be $176.8M in the next fiscal year. The high estimate is $183.7M and the low estimate is $170.9M.
